TORCH Testing

congenital infections

When you are pregnant, your greatest priority is protecting your baby. Congenital infections are caused by several pathogens that can be transmitted from the mother to the baby. These infections cause little to no symptoms in healthy adults; however, they severely affect the unborn fetus or newborn baby. Therefore, screening for these pathogens can help reduce the risk of fetal death and potentially life-threatening adverse effects. 

Abbott offers reliable and accurate TORCH testing solutions that can differentiate and help identify congenital infections early. TORCH is an acronym for a group of infections that can be transmitted from the mother to the baby during pregnancy, during childbirth, or shortly after birth:  Toxoplasma gondii, Rubella, Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), and other infections such as syphilis.1

 For in vitro diagnostic use.


10-30%

of all stillbirths have infectious etiology2 


~3%

of live births have congenital anomalies present2

 



Depending on the pathogen 

Up to 50%

of pregnancies with congenital infections may result in loss of a baby or fetal death2

 
 
 
HSV_CongenitalInfections_300x200.jpg

 

 

TORCH testing: Every baby deserves a healthy beginning

Healthcare providers are commonly challenged with unknown or potentially serious cases of prenatal infection.

Serological testing can help quickly confirm infection and substantially help reduce the risk of infection to the mother and a baby.

 

 



HSV_Torch-Testing_300x200.jpg

 

TORCH Barriers

 

Reducing the burden of congenital infections can be accomplished by overcoming some basic challenges.

 

Early Detection3

Early screening can play a role in the early identification of TORCH infections which may help reduce the risk of complications and life-threatening adverse effect to the baby.

HSV_Icon_TestingGuidelines_Green_300x200.png
Infection Awareness

Knowing one’s infection status can help increase the probability for receiving early treatment and valuable education on safe practices to reduce the risk of exposure.

HSV_Icon_InfectionAwareness_Green_300x200.png
Testing Guidelines

Many patients fail to be tested due to the absence of clear guidelines. Heightened global awareness among clinicians and the general population can accelerate early detection.

HSV_Icon_EarlyDetection_Green_300x200.png

 

 

 

  

Torch Panel Value

 


Harness the power of Abbott's TORCH panel to streamline testing, elevate performance, and help increase the probability of confidently identifying congenital infections.


 

HSV_Icon_ConfidentResults_Yellow_300x200.png

Confident Results

  • Highly specific assays
  • High sensitivity for the early detection of infection
  • Easy interpretation of results
  • Full automation from primary tube to result minimizes the chance of human error
  • Ready-to- use calibrators and controls reduces the possibility of reconstitution errors 

 

HSV_Icon_OptimizedEfficiency_Yellow_300x200.png

Optimized Efficiency

  • Consolidation of TORCH assays on Alinity i and ARCHITECT
  • Streamlines testing – minimizes hands-on time
  • Quick results reduce turn-around times
  • Highly specific assays - avoid re-runs and confirmation testing
  • Wide array of sample types: serum and plasma

 

Abbott's Assays
Toxo IgM | Toxo IgG | Toxo IgG Avidity | Rubella IgM | Rubella IgG | CMV IgM | CMV IgG | CMV IgG Avidity  
NOW AVAILABLE  HSV-1 IgG | HSV-2 IgG

 

 

 



Supporting
Publications

Learn more about the performance of Abbott's TORCH assays from peer reviewed journals.

Check back for more resources.

 

Publication Description
IgG Avidity Test to Discriminate between Acute and Chronic Toxoplasmosis Evaluation of the Abbott's ARCHITECT Avidity assay in detecting latent infection in the presence of persistent IgM.
Comparative evaluation of the ARCHITECT Toxo IgG, IgM and IgG Avidity assays for anti-Toxoplasma antibodies detection in pregnant women sera Study highlights the value of the Abbott's ARCHITECT for the analysis of all clinical situations concerning Toxoplasma gondii serology.
Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus An Italian study published in the Journal of Clinical Virology highlights the performance of the ARCHITECT analyzer in comparison with other commercial methods.
Evaluation of the New ARCHITECT Cytomegalovirus Immunoglobulin M (IgM), IgG, and IgG Avidity Assays A team of researchers from Belgium evaluates the ARCHITECT CMV immunoassays with several well-established comparator assays.
Evaluation of the Abbott ARCHITECT cytomegalovirus IgG/IgM, rubella IgG/IgM, and syphilis treponemal enzyme immunoassays in a mother and child health center population Researchers from Montreal, Quebec, Canada assessed chemiluminescent microparticle immunoassays in mixed pediatric and women of childbearing age population.
Comparison of the two fully automated anti-HCMV assays: Abbott ARCHITECT CMV IgG assay and Biotest anti-HCMV recombinant IgG ELISA A study published in Transfusion Medicine assessed the performance of CMIA and ELISA immunoassays under routine conditions in a transfusion laboratory.
Kinetics of CMV seroconversion in a Swiss pregnant population Evaluation of CMV serology to determine the utility and validity of recommended CMV serologic diagnostic algorithms.

 

 references
  1. TORCH. AACC: Lab Tests Online. https://labtestsonline.org/tests/torch. Updated September 22, 2020. Accessed March 3, 2021.
  2. Megli, Christina J, and Carolyn B Coyne. “Infections at the Maternal-Fetal Interface: An Overview of Pathogenesis and Defence.” Nature Reviews. Microbiology, Nature Publishing Group UK, 25 Aug. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386341/. 
  3. Wurcel, Victoria, et al. “The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems.” Public Health Genomics, vol. 22, no. 1-2, 2019, pp. 8–15., https://doi.org/10.1159/000501832. 

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No